Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Treasury Shares (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Treasury Shares data on record, last reported at $11.6 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 46.1% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, up 46.1%, while the annual FY2025 figure was $11.6 million, 46.1% up from the prior year.
  • Treasury Shares reached $11.6 million in Q4 2025 per MRVI's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $11.6 million in Q4 2025 and bottomed at $90000.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $5.0 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: crashed 74.21% in 2021, then skyrocketed 1378.89% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $90000.0 in 2021, then surged by 1378.89% to $1.3 million in 2022, then surged by 196.32% to $3.9 million in 2023, then surged by 101.47% to $7.9 million in 2024, then soared by 46.1% to $11.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $11.6 million in Q4 2025, $7.9 million in Q4 2024, and $3.9 million in Q4 2023.